The entry of Supect’s primary treatment is drawing near
‘Supect(ladotinib),’ a domestic new drug for chronic myeloid leukemia(CML), will soon become a primary treatment.
According to the industry concerned on the 27th, the indication expansion application which was turned in by Ilyang Pharmaceutical last July has been made and the Ministry of Food an...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
